Shorter Blood-Thinner Treatment After Heart Attack in High Bleeding Risk Patients
Tests a shorter, individualized blood-thinner plan in adults with heart attacks at high bleeding risk.
Plain-language title generated from the registry record
Registry title: Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Key facts
- Where
- Aalborg, Copenhagen, Hellerup, Odense, Roskilde, and Skejby, DenmarkSee the 6 sites
- Phase
- Phase 4
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- The Heart Centre, Copenhagen University Hospital, RigshospitaletCopenhagen, DenmarkTaking people
- Herlev and Gentofte University Hospital - GentofteHellerup, DenmarkTaking people
- Odense University HospitalOdense, DenmarkTaking people
- Zealand University HospitalRoskilde, DenmarkTaking people
- Aarhus University HospitalSkejby, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rikke Sorensen
- Trial code
- NCT05262803
- Record updated
- 15 March 2024
- Original description
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks. Over time, more potent antithrombotic drugs have been introduced like prasugrel and ticagrelor. These drugs have replaced the older drug, clopidogrel, as approximately 30% of patients are low-responders to clopidogrel for genetic reasons. However, the newer drugs introduce a significant risk of serious bleeding.Read full original descriptionShow less
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks. Over time, more potent antithrombotic drugs have been introduced like prasugrel and ticagrelor. These drugs have replaced the older drug, clopidogrel, as approximately 30% of patients are low-responders to clopidogrel for genetic reasons. However, the newer drugs introduce a significant risk of serious bleeding.
Aim: The aim of this trial is to assess a reduced antithrombotic strategy for high bleeding risk patients with heart attacks to reduce bleeding safely.
Hypothesis: Significantly reduced bleeding with a similar preventive effect are expected.
Design: The Dan-DAPT trial include high bleeding risk patients with heart attacks from Danish hospitals (Rigshospitalet, Aarhus, Odense, Aalborg, Roskilde, and Gentofte hospital) and randomize them to standard-of-care or shorter and individualized antithrombotic therapy based on responsiveness to clopidogrel after genetic testing.
Inclusion: MI caused by atherothrombotic CAD (Type 1 MI) according to "The Fourth Universal Definition of MI", which has been treated with PCI with contemporary drug-eluting stents. This definition of type 1 MI requires the detection of a rise and/or fall of cardiac troponin values with at least one value >99th percentile and at least one of the following criteria assessed by the treating physician:; symptoms indicating acute myocardial ischemia; new ischemic changes on the electrocardiogram; development of pathological Q-waves; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; visible coronary thrombus by angiography; PRECISE-DAPT score ≥25; Age ≥18 years.
Exclusion: Previous stent thrombosis; Prior intracranial hemorrhage; Contraindications including allergies to ASA or P2Y12 inhibitors; Resuscitated cardiac arrest with Glasgow Coma Scale <8 and/or need of intubation; Active bleeding (BARC ≥2) at randomization; Indication for oral anticoagulation; Life expectancy <1 year; Women who are pregnant, have given birth recently (within the past 90 days), are lactating, or are fertile without contraception; Hypertensive crisis (systolic blood pressure >180 mmHg and/or diastolic blood pressure >120 mmHg); Unable to understand and follow study-related instructions or to comply with study protocol.